ArticleBMC pediatrics2026
Improving diagnosis and management of pediatric ovarian masses: development of a risk stratification model incorporating sonographic and clinical features.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and validate a pediatric-specific prediction model for discriminating malignant from benign ovarian masses in Chinese children, aiming to reduce unnecessary surgeries for physiological follicular cysts.
methodsThis single-center retrospective study analyzed 344 consecutive patients ≤ 18 years undergoing ovarian surgery (2018–2024). Three blinded radiologists assessed sonographic parameters: maximum mass diameter and solid component proportion (Categorized as < 20%, 20–40%, 40–60%, 60–80%, > 80%). Multivariate logistic regression integrated clinical features, tumor markers, and sonographic variables to construct a malignancy prediction model. Diagnostic performance was evaluated by receiver operating characteristic (ROC) analysis.
resultsGerm cell tumors (GCTs) predominated (72.7%, 253/348), with malignant lesions comprising 11.5% (40/348). Solid component proportion > 80% was the strongest malignancy predictor (odds ratio[OR] = 576.5, 95% confidence intervals [CI]: 74.0–4,492.6; *p* < 0.001). The combined model (Mass size + Solid component proportion) achieved superior diagnostic accuracy (Area under the curve [AUC] = 0.93, sensitivity 87.5%, specificity 83.2%), outperforming single parameters (Solid component proportion AUC = 0.86; Mass size AUC = 0.76). In addition to key clinical discriminators such as older age, absence of precocious puberty, and larger tumor size, the exclusive presence of sonographic features like septations (28.3%) and calcifications (5.7%) in epithelial tumors (*p* < 0.001 vs. follicular cysts) provides a reliable basis for differentiation, enabling a significant reduction in unnecessary surgeries for physiological cysts.
conclusionThis study establishes an evidence-based prediction model for Chinese pediatric ovarian masses, redefining malignancy risk stratification through quantitative sonographic thresholds. Furthermore, it identifies key discriminators (Septations, Calcifications, alongside Age, Precocious puberty and Mass size) to differentiate physiological follicular cysts from neoplastic epithelial tumors. The integration of solid component proportion > 40% and tumor biomarkers optimizes preoperative decision-making, which can significantly reduce unwarranted surgery for benign conditions while ensuring timely intervention for high-risk cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.